Eli Lilly and Co.Foundayo SampleFoundayo™ (orforglipron) 0.8mg oral tablets. Oral GLP-1 receptor agonist. 30 film-coated tablets per bottle (starting dose, 30-day supply).
Indications and Usage
INDICATIONS AND USAGE
FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
Limitations of Use
Concomitant use with another GLP-1 receptor agonist is not recommended.
FAQsAll you need to know to order samples
Due to manufacturer restrictions, there are some limitations on the quantities of samples that can be included in each order. We're working on new functionality to let your practice place larger, batch orders.